Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Oct 2, 2013 2:17 PM Flag

    Perjeta label expanded

    based on phase II data, maybe Kadcyla is closer to expansion than we think? Kad + Per will be the new standard. Looks like the clown changed his name, but not his MO.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You would think at this point that at least one analyst would be able to piece together the overall strategy for Roche. Kadcyla will for all intent and purpose replace Herceptin and extend their hold on the franchise. Not only that, but Roche will expand the label into additional oncology targets. Pieces of this strategy are falling into place. Kadcyla will become at least a $9 billion dollar drug on breast cancer alone. Immunogen does not even need to hit their own home run with that future royalty stream coming in. All they need to do is pace themselves and not outspend what is coming in.

      Chinese Hamsters

 
IMGN
2.88-0.02(-0.69%)2:13 PMEDT